Zobrazeno 1 - 10
of 60
pro vyhledávání: '"HJ Gomez"'
Publikováno v:
Journal of Cardiovascular Pharmacology. 15:S26
Enalapril is an effective agent in the treatment of mild to severe hypertension. It is equally effective in elderly and young adult patients but appears to be more effective in white than in black hypertensive patients. Following treatment with enala
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e46e9e0bdce835e4470c27ba349f3cc8
https://doi.org/10.1097/00005344-199000153-00006
https://doi.org/10.1097/00005344-199000153-00006
Publikováno v:
Journal of Cardiovascular Pharmacology. 9:705-710
The acute hypotensive response to oral and parenteral enalapril (E) and lisinopril (LI) was assessed in 24 patients with chronic congestive heart failure in two open, randomized, balanced, crossover studies. In the E study, 12 patients received each
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cdb5780c02eb5dee18d0b6ea39f0c22
https://doi.org/10.1097/00005344-198706000-00011
https://doi.org/10.1097/00005344-198706000-00011
Autor:
Vincent J. Cirillo, C.E. Wilhelmsson, Anders Vedin, HJ Gomez, S Johansson, James A. Bolognese, H Herlitz, R. Bergstrand, Göran Berglund
Publikováno v:
British Journal of Clinical Pharmacology. 19:605-611
The dose-response relationship of enalapril was evaluated in a double-blind, balanced, two-period, incomplete-block study in 91 patients with mild to moderate essential hypertension. Patients were randomly assigned to two of six treatments: placebo,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37ff3a608ded9f66b1954db8e7de99e8
https://doi.org/10.1111/j.1365-2125.1985.tb02687.x
https://doi.org/10.1111/j.1365-2125.1985.tb02687.x
Publikováno v:
Drugs. 30:13-24
Enalapril, an orally-active, long-acting, nonsulphydryl angiotensin-converting enzyme (ACE) inhibitor, is extensively hydrolysed in vivo to enalaprilat, its bioactive form. Bioactivation probably occurs in the liver. Metabolism beyond activation to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f1516741824a2e9fa52ca291b757e3
https://doi.org/10.2165/00003495-198500301-00004
https://doi.org/10.2165/00003495-198500301-00004
Publikováno v:
British Journal of Clinical Pharmacology. 18:215S-229S
Enalapril maleate is a prodrug which when administered orally is hydrolysed to release the active converting enzyme inhibitor enalaprilat. Enalapril maleate is 60% absorbed and 40% bioavailable as enalaprilat. Both compounds undergo renal excretion w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f70cfb61e4251cf89a665f58d1988ad2
https://doi.org/10.1111/j.1365-2125.1984.tb02601.x
https://doi.org/10.1111/j.1365-2125.1984.tb02601.x
Publikováno v:
International Journal of Cardiology. 11:37-48
Following hemodynamic evaluation using invasive and noninvasive methods, 73 patients were treated in an open, uncontrolled, multicenter study with single oral doses of enalapril maleate 1.25 to 40 mg until the optimal dose for each patient (based upo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a830b1e196a7dc91be257f1d4e4b0ca
https://doi.org/10.1016/0167-5273(86)90197-x
https://doi.org/10.1016/0167-5273(86)90197-x
Publikováno v:
Journal of Cardiovascular Pharmacology. 9:S27-S34
Lisinopril is an orally active, nonsulfhydryl angiotensin-converting-enzyme (ACE) inhibitor that is not metabolized or bound to protein. Peak serum concentrations occur 6-8 h after oral dosing. Lisinopril bioavailability (approximately 25%) is not si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b736cf118fddfa5a5b3dd5fe05442b9
https://doi.org/10.1097/00005344-198700003-00008
https://doi.org/10.1097/00005344-198700003-00008
Autor:
R Nyberg, HJ Gomez, K Kristianson, J Salonen, R Salonen, James A. Bolognese, Vincent J. Cirillo, V Rissanen
Publikováno v:
British Journal of Clinical Pharmacology. 25:533-538
1. The dose-peak effect relationship of lisinopril was evaluated in a double-blind, parallel study in 83 patients with mild to moderate essential hypertension (supine diastolic blood pressure = 95-115 mm Hg). 2. After a 4 week placebo washout, patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::159733cac6c5e00237c2417570b8021a
https://doi.org/10.1111/j.1365-2125.1988.tb03342.x
https://doi.org/10.1111/j.1365-2125.1988.tb03342.x
Autor:
William B. Abrams, Turini Ga, HJ Gomez, Hans R. Brunner, K. H. Jones, M Burnier, M. Porchet, D. B. Brunner, Jérôme Biollaz, Gavras H, F Ferber
Publikováno v:
Clinical Pharmacology and Therapeutics. 29:665-670
Three new angiotensin converting-enzyme inhibitors were given orally to 20 men in single doses ranging from 1.25 to 40 mg. Two of them induced comparable marked inhibition of both the blood pressure response to exogenous angiotensin I and plasma conv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4e1cefd1104f6c56889d74430876e2c
https://doi.org/10.1038/clpt.1981.92
https://doi.org/10.1038/clpt.1981.92